Skip to main content
Top
Published in: BMC Health Services Research 1/2012

Open Access 01-12-2012 | Research article

How much are we spending? The estimation of research expenditures on cardiovascular disease in Canada

Authors: Claire de Oliveira, Van Hai Nguyen, Harindra C Wijeysundera, William W L Wong, Gloria Woo, Peter P Liu, Murray D Krahn

Published in: BMC Health Services Research | Issue 1/2012

Login to get access

Abstract

Background

Cardiovascular disease (CVD) is a leading cause of death in Canada and is a priority area for medical research. The research funding landscape in Canada has changed quite a bit over the last few decades, as have funding levels. Our objective was to estimate the magnitude of expenditures on CVD research for the public and charitable (not-for profit) sectors in Canada between 1975 and 2005.

Methods

To estimate research expenditures for the public and charitable sectors, we compiled a complete list of granting agencies in Canada, contacted each agency and the Canadian Institutes of Health Research (CIHR), and extracted data from the organizations’ annual reports and the Reference Lists of health research in Canada. Two independent reviewers scanned all grant and fellowship/scholarship titles (and summary/key words, when available) of all research projects funded to determine their inclusion in our analysis; only grants and fellowships/scholarships that focused on heart and peripheral vascular diseases were selected.

Results

Public/charitable sector funding increased 7.5 times, from close to $13 million (in constant dollars) in 1975 to almost $96 million (in constant dollars) in 2005 (base year). The Medical Research Council of Canada (MRCC)/CIHR and the Heart & Stroke Foundation of Canada have been the main founders of this type of research during our analysis period; the Alberta Heritage Foundation for Medical Research and the Fonds de la recherche en santé du Quebec have played major roles at the provincial level. The Indirect Costs Research Program and Canada Foundation for Innovation have played major roles in terms of funding in the last years of our analysis.

Conclusion

Public/charitable-funded research expenditures devoted to CVD have increased substantially over the last three decades. By international standards, the evidence suggests Canada spends less on health-related research than the UK and the US, at least in absolute terms. However, this may not be too problematic as Canada is likely to free-ride from research undertaken elsewhere. Understanding these past trends in research funding may provide decision makers with important information for planning future research efforts. Future work in this area should include the use of our coding methods to obtain estimates of funded research for other diseases in Canada.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wooding S, Hanney S, Pollitt A, Buxton M, Grant J: Project Retrosight – Understanding the returns from cardiovascular and stroke research. 2011, CA: RAND Corporation Wooding S, Hanney S, Pollitt A, Buxton M, Grant J: Project Retrosight – Understanding the returns from cardiovascular and stroke research. 2011, CA: RAND Corporation
2.
go back to reference Bliss M, Beyond the Granting Agency The Medical Research Council in the 1990s: Medical Research Council of Canada. Public Works and Government Services Canada. 2000, Ottawa, Ontario Canada: Medical Research Council of Canada, Cat. No. MR21-20/2000 ISBN 0-662-64891-9 Bliss M, Beyond the Granting Agency The Medical Research Council in the 1990s: Medical Research Council of Canada. Public Works and Government Services Canada. 2000, Ottawa, Ontario Canada: Medical Research Council of Canada, Cat. No. MR21-20/2000 ISBN 0-662-64891-9
3.
go back to reference Poulin BJ, Gordon R: How to organize science funding: the new Canadian Institutes for Health Research (CIHR), an opportunity to vastly increase innovation. Canadian Public Policy. 2001, 27 (1): 95-112. 10.2307/3552376.CrossRef Poulin BJ, Gordon R: How to organize science funding: the new Canadian Institutes for Health Research (CIHR), an opportunity to vastly increase innovation. Canadian Public Policy. 2001, 27 (1): 95-112. 10.2307/3552376.CrossRef
4.
go back to reference McMurtry R: An Overview of Health Research Funding in Canada. 2000, Summer: Hospital Quarterly, 16-18. McMurtry R: An Overview of Health Research Funding in Canada. 2000, Summer: Hospital Quarterly, 16-18.
5.
go back to reference Charbonneau L: MRC changes its name, doubles its budget. Can Med Assoc J. 2000, 162 (7): 1029. Charbonneau L: MRC changes its name, doubles its budget. Can Med Assoc J. 2000, 162 (7): 1029.
7.
go back to reference Nason E: Health and Medical Research in Canada – Observatory on Health Research Systems. 2008, Santa Monica, CA: RAND Corporation Nason E: Health and Medical Research in Canada – Observatory on Health Research Systems. 2008, Santa Monica, CA: RAND Corporation
8.
go back to reference Salganik MJ: Variance estimation, design effects, and sample size calculations for respondent-driven sampling. J Urban Health. 2006, 83: i98-i112. 10.1007/s11524-006-9106-x.CrossRefPubMed Salganik MJ: Variance estimation, design effects, and sample size calculations for respondent-driven sampling. J Urban Health. 2006, 83: i98-i112. 10.1007/s11524-006-9106-x.CrossRefPubMed
9.
go back to reference Medical Research Council (Canada): Reference List of Health Science Research in Canada. 1975–1999, Ottawa, Canada: Répertoire de Recherches en Santé Au Canada Medical Research Council (Canada): Reference List of Health Science Research in Canada. 1975–1999, Ottawa, Canada: Répertoire de Recherches en Santé Au Canada
11.
go back to reference Blume-Kohout ME: Does Targeted Disease-Specific Public Research Funding Influence Pharmaceutical Innovation?. J Policy Anal Manage. 2012, 31 (3): 641-660. 10.1002/pam.21640.CrossRefPubMed Blume-Kohout ME: Does Targeted Disease-Specific Public Research Funding Influence Pharmaceutical Innovation?. J Policy Anal Manage. 2012, 31 (3): 641-660. 10.1002/pam.21640.CrossRefPubMed
12.
go back to reference Lichtenberg FR: The allocation of public funds for biomedical R&D. 1999, Washington, DC: AEI Press Lichtenberg FR: The allocation of public funds for biomedical R&D. 1999, Washington, DC: AEI Press
13.
go back to reference Toole AA: Does public scientific research complement private investment in research and development in the pharmaceutical industry?. J Law Econ. 2007, 50: 81-104. 10.1086/508314.CrossRef Toole AA: Does public scientific research complement private investment in research and development in the pharmaceutical industry?. J Law Econ. 2007, 50: 81-104. 10.1086/508314.CrossRef
14.
go back to reference Toole AA: The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry. Res Policy. 2012, 41: 1-12. 10.1016/j.respol.2011.06.004.CrossRef Toole AA: The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry. Res Policy. 2012, 41: 1-12. 10.1016/j.respol.2011.06.004.CrossRef
15.
go back to reference Dorsey ER, Thompson JP, Carrasco M, de Roulet J, Vitticore P, et al: Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic Areas. PLoS One. 2009, 4 (9): e7015-10.1371/journal.pone.0007015.CrossRefPubMedPubMedCentral Dorsey ER, Thompson JP, Carrasco M, de Roulet J, Vitticore P, et al: Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic Areas. PLoS One. 2009, 4 (9): e7015-10.1371/journal.pone.0007015.CrossRefPubMedPubMedCentral
16.
go back to reference Gross CP, Anderson GF, Powe NR: The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med. 1999, 340: 1881-1887. 10.1056/NEJM199906173402406.CrossRefPubMed Gross CP, Anderson GF, Powe NR: The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med. 1999, 340: 1881-1887. 10.1056/NEJM199906173402406.CrossRefPubMed
17.
go back to reference Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, Tu JV, Lee DS, Goodman SG, Petrella R, O’Flaherty M, Krahn M, Capewell S: Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. J Am Med Assoc. 2010, 303 (18): 1841-1847. 10.1001/jama.2010.580.CrossRef Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, Tu JV, Lee DS, Goodman SG, Petrella R, O’Flaherty M, Krahn M, Capewell S: Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. J Am Med Assoc. 2010, 303 (18): 1841-1847. 10.1001/jama.2010.580.CrossRef
18.
go back to reference Buxton M, Hanney S, Morris S, Sundmacher L, Mestre-Ferrandiz J, Garau M, Sussex J, Grant J, Ismail S, Nason E, Wooding S, Kapur S: Medical Research: What’s it worth? Estimating the economic benefits from medical research in the UK. 2008, London, UK: Evaluation Forum Buxton M, Hanney S, Morris S, Sundmacher L, Mestre-Ferrandiz J, Garau M, Sussex J, Grant J, Ismail S, Nason E, Wooding S, Kapur S: Medical Research: What’s it worth? Estimating the economic benefits from medical research in the UK. 2008, London, UK: Evaluation Forum
19.
go back to reference Statistics Canada: The Consumer Price Index. Catalogue no. 62-001-X. 2011, Ottawa, Ontario: Statistics Canada; January 2011Edition Statistics Canada: The Consumer Price Index. Catalogue no. 62-001-X. 2011, Ottawa, Ontario: Statistics Canada; January 2011Edition
20.
go back to reference Eni G: Biomedical and Health Services Research in Canada: A Review. Healthc Manage Forum. 1992, 5 (3): 21-30. 10.1016/S0840-4704(10)61212-4.CrossRefPubMed Eni G: Biomedical and Health Services Research in Canada: A Review. Healthc Manage Forum. 1992, 5 (3): 21-30. 10.1016/S0840-4704(10)61212-4.CrossRefPubMed
22.
go back to reference Tu JV, Nardi L, Fang J, Liu J, Khalid L, Johansen H, Canadian Cardiovascular Outcomes Research Team: National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke. Can Med Assoc J. 2009, 180 (13): E113-E125.CrossRef Tu JV, Nardi L, Fang J, Liu J, Khalid L, Johansen H, Canadian Cardiovascular Outcomes Research Team: National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke. Can Med Assoc J. 2009, 180 (13): E113-E125.CrossRef
23.
go back to reference de Oliveira C, Nguyen VH, Wijeysundera H, Wong W, Woo G, Grootendorst P, Liu P, Krahn M: Is investing in research worth it? Estimating the internal rate of return of investing in cardiovascular disease research in Canada. Working Paper. 2012, Toronto, Ontario Canada: Toronto Health Economics Technology Assessment Collaborative de Oliveira C, Nguyen VH, Wijeysundera H, Wong W, Woo G, Grootendorst P, Liu P, Krahn M: Is investing in research worth it? Estimating the internal rate of return of investing in cardiovascular disease research in Canada. Working Paper. 2012, Toronto, Ontario Canada: Toronto Health Economics Technology Assessment Collaborative
24.
go back to reference Varmus H: Evaluating the Burden of Disease and Spending the Research Dollars of the National Institutes of Health. N Engl J Med. 1999, 340: 1914-1915. 10.1056/NEJM199906173402411.CrossRefPubMed Varmus H: Evaluating the Burden of Disease and Spending the Research Dollars of the National Institutes of Health. N Engl J Med. 1999, 340: 1914-1915. 10.1056/NEJM199906173402411.CrossRefPubMed
Metadata
Title
How much are we spending? The estimation of research expenditures on cardiovascular disease in Canada
Authors
Claire de Oliveira
Van Hai Nguyen
Harindra C Wijeysundera
William W L Wong
Gloria Woo
Peter P Liu
Murray D Krahn
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2012
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-12-281

Other articles of this Issue 1/2012

BMC Health Services Research 1/2012 Go to the issue